Resource Summary Report

Generated by dkNET on Aug 13, 2026

FGF Receptor 1 (D8E4) XP Rabbit mAb

RRID:AB_11178519
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9740, RRID:AB_11178519

Antibody Information

URL: http://antibodyregistry.org/AB_11178519

Proper Citation: Cell Signaling Technology Cat# 9740, RRID:AB_11178519

Target Antigen: FGF Receptor 1 (D8E4) XP Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, IF-IC, F. Consolidation on 10/2018: AB_11178519, AB_11178808.

Antibody Name: FGF Receptor 1 (D8E4) XP Rabbit mAb

Description: This monoclonal targets FGF Receptor 1 (D8E4) XP Rabbit mAb

Target Organism: rat, h, m, mouse, r, human, mk

Antibody ID: AB_11178519

Vendor: Cell Signaling Technology

Catalog Number: 9740

Record Creation Time: 20250820T000300+0000

Record Last Update: 20250820T071305+0000

Ratings and Alerts

No rating or validation information has been found for FGF Receptor 1 (D8E4) XP Rabbit mAb.

No alerts have been found for FGF Receptor 1 (D8E4) XP Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 41 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Entrialgo-Cadierno R, et al. (2026) Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma. Cancer cell, 44(6), 1218.

Boudjadi S, et al. (2026) Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma. Molecular cancer therapeutics, 25(3), 493.

Juric D, et al. (2026) PI3K? Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(1), 56.

Kostas M, et al. (2026) Unconventional activation of the proto-oncogene FGFR1 by extracellular phosphate via H2O2-mediated kinase oxidation. Cell reports, 45(6), 117504.

Yuan L, et al. (2025) STEAP3 promotes triple-negative breast cancer growth through the FGFR1-mediated activation of PI3K/AKT/mTOR signaling. iScience, 28(6), 112526.

Gu Y, et al. (2025) Clioquinol inhibits angiogenesis by promoting VEGFR2 degradation and synergizes with AKT inhibition to suppress triple-negative breast cancer vascularization. Angiogenesis, 28(2), 13.

Madorsky Rowdo FP, et al. (2025) Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition. Cancer research, 85(3), 551.

Dalangood S, et al. (2025) Cancer-associated adipocytes mediate CD8+T cell dysfunction via FGF21-driven lipolysis. Cell reports, 44(11), 116526.

Yeh CJ, et al. (2025) FGFR1 and FGFR4 are essential regulators of muscle stem cell quiescence. Cell communication and signaling : CCS, 23(1), 535.

Anastasaki C, et al. (2025) Aberrant coupling of glutamate and tyrosine kinase receptors enables neuronal control of brain-tumor growth. Neuron.

House NC, et al. (2025) CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. NPJ breast cancer, 11(1), 135.

Hu C, et al. (2024) Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8+T cells. Cell metabolism, 36(3), 630.

Edman NI, et al. (2024) Modulation of FGF pathway signaling and vascular differentiation using designed oligomeric assemblies. Cell, 187(14), 3726.

Choi YR, et al. (2023) Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer. British journal of cancer.

Ma L, et al. (2023) Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric Cancer. Journal of medicinal chemistry, 66(11), 7438.

Vad-Nielsen J, et al. (2023) Genome-wide epigenetic and mRNA-expression profiling followed by CRISPR/Cas9-mediated gene-disruptions corroborate the MIR141/MIR200C-ZEB1/ZEB2-FGFR1 axis in acquired EMT-associated EGFR TKI-resistance in NSCLC cells. Translational lung cancer research, 12(1), 42.

Shin S, et al. (2023) mTOR inhibition reprograms cellular proteostasis by regulating eIF3D-mediated selective mRNA translation and promotes cell phenotype switching. Cell reports, 42(8), 112868.

Mitchell AV, et al. (2022) DDR2 coordinates EMT and metabolic reprogramming as a shared effector of FOXQ1 and SNAI1. Cancer research communications, 2(11), 1388.

Schaefer EJ, et al. (2022) BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes. Blood cancer discovery, 3(2), 116.

Li H, et al. (2022) Pro-prion, as a membrane adaptor protein for E3 ligase c-Cbl, facilitates the ubiquitination of IGF-1R, promoting melanoma metastasis. Cell reports, 41(12), 111834.